Rockwell Medical Technologies
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Rockwell Medical Technologies sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Rockwell Medical Technologies: 15 sponsored US clinical trials, none currently recruiting.
Rockwell Medical Technologies sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 15 completed. 4 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is End Stage Renal Disease, with 2 trials.
Top-decile sponsor footprint
Rockwell Medical Technologies ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
15 total, page 1 of 1
Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
NCT04689932
Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.
NCT04409132
A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients
NCT04042324
Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
NCT03303144
Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers
NCT02767128
Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
NCT02739100
Triferic Pediatric Pharmacokinetic Protocol
NCT02595437
Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers
NCT02636049
Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients
NCT01894906
A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.
NCT01920854
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis
NCT01503021
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)
NCT01322347
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
NCT01320202
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
NCT01286012
Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis
NCT00548249
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 2 |
| Phase 3 | 3 |
| Phase 4 | 1 |
How the Rockwell Medical Technologies early-phase archive is shaped
15 indexed studies, none listed as recruiting (0% open); 15 completed (100%).
Phase mix: 4 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: End Stage Renal Disease (2 trials), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Rockwell Medical Technologies: archived-pipeline peers nationwide
Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Rockwell Medical Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 archived trials
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Rockwell Medical Technologies page
15 registered trials is a research-attention snapshot, not an endorsement of Rockwell Medical Technologies or any single study.
- None of Rockwell Medical Technologies's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- End Stage Renal Disease is the condition Rockwell Medical Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See End Stage Renal Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Rockwell Medical Technologies pipeline card: 15 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.